Preclinical Development Discussion: The "Black Box" between Med Chem and Clinical
Jennifer Martin
Senior Advisor-ADME, Eli Lilly and Company
A discussion with pharma leaders on the roadmap for early development with Tox, ADME, CMC and Phase 1 clinical design. Topics include Toxicity program for peptides, how to pick clinical dose, and preclinical to clinical translation. Panelists brought their experiences and discussed lessons learned in short presentations and a moderated roundtable.
Jennifer A Martin, MS is a Senior Advisor in Drug Disposition at Eli Lilly and Company in Indianapolis, Indiana. I design, analyze, and interpret studies for the absorption/distribution/metabolism/excretion (ADME) of large molecule compounds in support of ADME, pharmacology, and toxicology studies. I provide scientific consultation and expertise on cross-functional program teams to design development plans, recommend selection of drug candidates for development, and prepare for worldwide regulatory submissions.